Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Urelumab (BMS-663513) is an activating monoclonal antibody that targets CD137, resulting in activation of CD137-expressing immune cells, thereby enhancing T-cell mediated response to tumor cells (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Urelumab||anti-CD137 monoclonal antibody|BMS-663513||Urelumab (BMS-663513) is an activating monoclonal antibody that targets CD137, resulting in activation of CD137-expressing immune cells, thereby enhancing T-cell mediated response to tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02252263||Phase I||Urelumab Lirilumab Elotuzumab||A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma||Completed|
|NCT02658981||Phase I||Relatlimab Urelumab Nivolumab + Urelumab Nivolumab + Relatlimab||Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)||Active, not recruiting|
|NCT02845323||Phase II||Urelumab Nivolumab + Urelumab||Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder||Recruiting|
|NCT02652455||Phase I||Nivolumab Aldesleukin + Cyclophosphamide + Fludarabine Urelumab||Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma||Active, not recruiting|